Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Volume: 148, Issue: 7, Pages: 1320 - 1329
Published: Jun 1, 2015
Abstract
Background & Aims null Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC. null Methods null We performed...
Paper Details
Title
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Published Date
Jun 1, 2015
Volume
148
Issue
7
Pages
1320 - 1329
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.